Armstrong Advisory Group’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Armstrong Advisory Group’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-45	Closed	-$604	–	849
2024 Q1	$604	Hold	45	–	–	﹤0.01%	746
2023 Q4	$604	Hold	45	–	–	﹤0.01%	746
2023 Q3	$555	Hold	45	–	–	﹤0.01%	813
2023 Q2	$554	Hold	45	–	–	﹤0.01%	778
2023 Q1	$554	Hold	45	–	–	﹤0.01%	759
2022 Q4	$516	Buy	+45	New	+$371	﹤0.01%	785

Other funds holding MACK

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Rise Advisors Rochester, New York $355M AUM 20.51% 1-Year Est. Return

JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Armstrong Advisory Group's MACK Position: Q2 2024 in Review

Armstrong Advisory Group sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 45 shares — an estimated $604 sold.

Armstrong Advisory Group first reported a position in MACK in Q4 2022 and held it in 6 quarters. The position peaked at $604 in Q1 2024. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.

Armstrong Advisory Group reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
Armstrong Advisory Group sold 45 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $604.
Armstrong Advisory Group first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2022 and held it in 6 quarters.
Armstrong Advisory Group's Merrimack Pharmaceuticals, Inc. position peaked at $604 in Q1 2024.
12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.

Based on Armstrong Advisory Group's 13F filing for Q2 2024, filed 12 Jul 2024.